Bone remodelling markers in rheumatoid arthritis.

Area of Science:

• Rheumatology
• Bone Metabolism
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is characterized by chronic inflammation leading to significant bone loss, increasing osteoporosis and fracture risks.
• Bone resorption in RA, whether periarticular or systemic, is driven by osteoclast activation, influenced by a decreased osteoprotegerin/receptor activator of nuclear factor kappa-B ligand (OPG/RANKL) ratio and proinflammatory cytokines.

Purpose of the Study:

• To review changes in bone remodeling markers in rheumatoid arthritis (RA) patients undergoing treatment with biologic agents.
• To highlight the role of bone remodeling markers in assessing the efficacy of biologic therapies in mitigating RA-associated bone loss.

Main Methods:

• Review of existing literature on bone remodeling markers in RA.
• Analysis of studies evaluating biologic agents' impact on bone metabolism markers in RA patients.

Main Results:

• Specific bone formation markers (e.g., osteocalcin, PINP, ICTP, BAP) and resorption markers (e.g., I-CTX, I-NTX, DPD, PYD, TRAP) are utilized in RA management.
• Biologic agents used in RA treatment demonstrate a protective effect on bone by reducing inflammation and influencing bone remodeling markers.

Conclusions:

• Bone remodeling markers are crucial for monitoring disease activity and treatment response in RA patients.
• Biologic therapies offer a promising approach to preserve bone health in RA by modulating inflammatory pathways and bone turnover.